SIGA (SIGA)
Supplies oral and IV TPOXX for smallpox preparedness programs.
Something off on this page? Send us feedback.
Commercial-stage health-security drug maker centered on TPOXX, an oral and IV smallpox antiviral sold mainly through U.S. and international government procurement. Revenue sits in one reportable segment and depends on BARDA contracts, stockpile deliveries, international biodefense demand, and TPOXX label expansion.
Sells oral TPOXX to the U.S. Government and international governments, and IV TPOXX to the U.S. Government for smallpox preparedness. The business is organized as one reportable segment covering TPOXX product sales and research-and-development services.
Execution centers on government procurement, BARDA contract work, stockpile delivery, and regulated product labels. U.S. use is approved for smallpox, while mpox access in the U.S. runs through CDC expanded access and some non-U.S. labels cover broader orthopox indications.
Customer concentration, BARDA funding, international biodefense demand, and approval of additional formulations shape the operating model.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $117.6M · Total debt $439.4K · Total assets $175.7M · Shareholders' equity $165.3M
- Revenue
- $41.0M
- Operating income
- $13.9M
- Net income
- $12.5M
| Institutions | 48.96% | 35.18M shares | |
|---|---|---|---|
| 165 holders · as of Jun 30, 2026 | |||
| Insiders | 6.11% | 4.39M shares | |
| 12 holders · as of Jun 10, 2026 | |||
| Other | 44.93% | 32.28M shares | |
| remainder | |||
71.85M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
BlackRock, Inc.Institution | 5.83% | 4.19M | as of Jun 30, 2026 |
Andrew SoleInsider | 4.31% | 3.10M | filed Nov 22, 2021 |
Dimensional Fund Advisors LPInstitution | 3.79% | 2.72M | as of Jun 30, 2026 |
Altravue Capital, LLCInstitution | 3.24% | 2.33M | as of Jun 30, 2026 |
Vanguard Capital Management LLCInstitution | 2.38% | 1.71M | as of Jun 30, 2026 |
Insider tradesForm 4
No open-market trades in the last 12 months.
- Emergent BioSolutions
Direct smallpox MCM peer with TEMBEXA and ACAM2000
- GeoVax Labs
Investigational second-source MVA orthopox vaccine developer
- Tonix Pharmaceuticals
Early-stage mpox/smallpox vaccine candidate with CBRN funding
- Soligenix
Broader biodefense MCM developer competing for preparedness funds
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| SIGA | $3.15 | −3.53% | $233.8M | — | — | 4.4 | −49.5% |
| Emergent BioSolutions | $6.65 | −1.63% | $348.8M | — | — | 0.5 | +66.3% |
| GeoVax Labs | $0.3797 | +4.51% | $2.7M | — | — | — | — |
| Tonix Pharmaceuticals | $10.14 | −4.25% | $168.8M | — | — | 5.8 | +577.9% |
| Soligenix | $0.3832 | −0.47% | $5.7M | — | — | — | — |
| Median | — | — | 3.1 | +322.1% |